(Reuters) -Abbott will buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking ...

The proposed deal, the biggest under CEO Robert Ford’s tenure, would allow Abbott to enter a large, new market for cancer ...

Madison-based Exact Sciences will be acquired by Abbott Laboratory for roughly $23 billion in a deal that was announced Nov.

Successful tech-based companies become so in different ways, a phenomenon on display of late with the announced $23 billion acquisition of Wisconsin’s Exact Sciences by Illinois-based Abbott ...

Exact Sciences, which bought Bay Area cancer testing pioneer Genomic Health in 2019, is projected to generate more than $3 ...

Abbott agrees to acquire Exact Sciences for an estimated value up to $23 billion. The acquisition will include Exact Sciences' cancer ...

Pharmaceutical company Abbott will be acquiring Madison-based cancer research company Exact sciences for $21 billion, the ...

The company will maintain its presence in Madison and CEO Kevin Conroy will remain “in an advisory role,” said Zach Brandon, ...

Founded near Boston in 1995, the company grew to become a biotech giant largely on the strength of its Cologuard cancer ...

Abbott announces a $21 billion all-cash deal to acquire Exact Sciences. Here's why EXAS shares are unlikely to push any ...

By bringing Exact Sciences into the fold, the expectation is that the focus on cancer diagnostics can provide a jolt to the ...